Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Jain

Showing results (341-350 of 420) with videos related to

Pageof 42
Sort By:
American Journal of Hematology|March 28, 2024
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populationsTeresa Caprice, Wenyi Fan, Jongphil Kim, et al.
Blood Advances|July 11, 2022
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCLAriel Perez, Grace Johnson, Kedar Patel, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11Michael D Jain, David B Miklos, Caron A Jacobson, et al.
Transplantation and Cellular Therapy|December 29, 2024
Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene CiloleucelAasha I Hoogland, Xiaoyin Li, Karnav Modi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
Delays and barriers to early treatment initiation for childhood tuberculosis in IndiaC Valvi, A Chandanwale, S Khadse, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Nature Medicine|December 1, 2001
Annexin-V imaging for noninvasive detection of cardiac allograft rejectionJ Narula, E R Acio, N Narula, et al.
Pageof 42

Showing results (341-350 of 420) with videos related to

Sort By:
Pageof 42
American Journal of Hematology|March 28, 2024
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populationsTeresa Caprice, Wenyi Fan, Jongphil Kim, et al.
Blood Advances|July 11, 2022
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCLAriel Perez, Grace Johnson, Kedar Patel, et al.
Blood Advances|January 5, 2024
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortalityKai Rejeski, Yucai Wang, Doris K Hansen, et al.
Blood|April 27, 2022
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphomaMichael D Jain, Bachisio Ziccheddu, Caroline A Coughlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11Michael D Jain, David B Miklos, Caron A Jacobson, et al.
Transplantation and Cellular Therapy|December 29, 2024
Real-World Patient-Reported and Neurocognitive Outcomes in the Year After Axicabtagene CiloleucelAasha I Hoogland, Xiaoyin Li, Karnav Modi, et al.
International Journal of Radiation Oncology, Biology, Physics|July 9, 2021
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell TherapyNicholas B Figura, Timothy J Robinson, Austin J Sim, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2019
Delays and barriers to early treatment initiation for childhood tuberculosis in IndiaC Valvi, A Chandanwale, S Khadse, et al.
International Journal of Radiation Oncology, Biology, Physics|June 9, 2019
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell LymphomaAustin J Sim, Michael D Jain, Nicholas B Figura, et al.
Nature Medicine|December 1, 2001
Annexin-V imaging for noninvasive detection of cardiac allograft rejectionJ Narula, E R Acio, N Narula, et al.
Pageof 42